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Understanding the control of myelin formation by
oligodendrocytes is essential for treating demyelin-
ating diseases. Neuregulin-1 (NRG1) type III, an
EGF-like growth factor, is essential for myelination
in the PNS. It is thus thought that NRG1/ErbB signal-
ing also regulates CNS myelination, a view sug-
gested by in vitro studies and the overexpression of
dominant-negative ErbB receptors. To directly test
this hypothesis, we generated a series of conditional
null mutants that completely lack NRG1 beginning
at different stages of neural development. Unexpect-
edly, these mice assemble normal amounts of mye-
lin. In addition, double mutants lacking oligoden-
droglial ErbB3 and ErbB4 become myelinated in the
absence of any stimulation by neuregulins. In con-
trast, a significant hypermyelination is achieved by
transgenic overexpression of NRG1 type I or NRG1
type III. Thus, NRG1/ErbB signaling is markedly
different between Schwann cells and oligodendro-
cytes that have evolved an NRG/ErbB-independent
mechanism of myelination control.
INTRODUCTION
The neuronal growth factor Neuregulin-1 (NRG1) comprises
a family of more than 15 transmembrane and secreted proteins,
derived from one of the largest mammalian genes. All NRG1 sub-
types share an epidermal growth factor (EGF)-like signaling do-
main and can be classified into subgroups through their different
amino termini (Falls, 2003). NRG1 isoforms type I and type II have
N-terminal Ig-like domains and, following proteolytic cleavage,
can be shed and released as soluble proteins from the neuronalcell surface. NRG1 type III is defined by a cysteine-rich domain
(CRD), has two transmembrane domains, and is tightly associ-
ated with axonal membranes (Esper et al., 2006; Nave and
Salzer, 2006).
The best understood function of NRG1 is the control of myeli-
nation in the peripheral nervous system (PNS), where NRG1 is
essential for glial and neuronal survival, the proliferation of
Schwann cells, and their terminal differentiation (Garratt et al.,
2000a; Nave and Salzer, 2006). In development, a threshold level
of axonal Nrg1 type III is required to induce myelination by
Schwann cells in vitro and in vivo (Taveggia et al., 2005)
(M.H.S. et al., unpublished data). Both Schwann cell expansion
and myelination require glial ErbB2 receptors (Garratt et al.,
2000b). Subsequently, the amount of NRG1 type III expressed
on myelinated axons determines myelin sheath thickness
(Michailov et al., 2004). At this stage, proteolytic processing
may be required to fully activate NRG1 type III (Hu et al., 2006;
Sagane et al., 2005; Willem et al., 2006).
In the central nervous system (CNS), NRG1/ErbB signaling has
been implicated in a broad range of roles, including neuronal mi-
gration, axonal pathfinding, and synaptic function (Flames et al.,
2004; Lopez-Bendito et al., 2006;Mei andXiong,2008).NRG1sig-
naling also affects oligodendrocyte specification, differentiation,
myelination, andsurvival, at least in vitro (Calaora et al., 2001;Can-
oll et al., 1996, 1999; Flores et al., 2000; Vartanian et al., 1997).
The embryonic lethality of null mutations has hampered the
in vivo analysis ofNrg1 and ErbB in the nervous system (Adlkofer
and Lai, 2000; Garratt et al., 2000b). Nevertheless, several
ex vivo studies supported a possible role of both genes in oligo-
dendrocyte differentiation and myelination (Fernandez et al.,
2000; Park et al., 2001; Sussman et al., 2005; Vartanian et al.,
1999). Moreover, heterozygous NRG1 type III mutants were re-
ported to be hypomyelinated (Taveggia et al., 2008), and trans-
genic mice overexpressing dominant-negative ErbB receptors
in oligodendrocytes (Kim et al., 2003; Roy et al., 2007) suggested
a critical function of NRG1/ErbB signaling in CNS myelination.Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc. 581
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gene in human schizophrenia (Law et al., 2006; Stefansson
et al., 2002) has renewed interest in the contribution of NRG1/
ErbB signaling to mammalian brain development, including
CNS myelination, as some patients with schizophrenia show
white matter abnormalities (Corfas et al., 2004). In addition, the
demonstration of a myelin-promoting function of NRG1 in vivo
could aid the development of a therapeutic strategy for demye-
linating diseases such as multiple sclerosis.
To determine the consequences of altered NRG1/ErbB signal-
ing on brain development, and specifically on the myelination of
CNS fiber tracts, we generated and analyzed a large battery of
mice with reduced Nrg1 gene dosage, neuronal NRG1 over-
expression, various conditional Nrg1 null mutations (defined
by Cre recombination at different stages of development), and
mice lacking oligodendroglial ErbB3 and ErbB4 receptors. Col-
lectively, these data demonstrate that axonal NRG1/ErbB signal-
ing plays a fundamentally different role in central and peripheral
myelination.
RESULTS
Many CNS axons are first myelinated by oligodendrocytes and
then by Schwann cells as they exit the spinal cord. Schwann
cells can also invade the demyelinated CNS and ensheath cen-
tral axons. These observations suggest that the axonal signals
controlling myelin formation are conserved in the central and
peripheral nervous systems (Colello and Pott, 1997; Duncan
and Hoffman, 1997). Since heterozygous Nrg1 null (affecting all
isoforms) mice exhibit a significant hypomyelination of axons in
the PNS (Michailov et al., 2004; Taveggia et al., 2005), we antic-
ipated a corresponding hypomyelination also in CNS white mat-
ter tracts. Surprisingly, analysis of the optic nerve, corpus cal-
losum, and spinal cord of adult Nrg1 null heterozygous (+/)
mice revealed no such reduction of myelin sheath thickness by
electron microscopy (Figure S1A) and subsequent calculation
of g ratios when plotted as a function of the axonal caliber (Fig-
ure S1B). Also, mice heterozygous for only the NRG1 type III iso-
form (Wolpowitz et al., 2000) exhibited normal myelin thickness
in the corpus callosum (Figures S1C and S1D). Both findings
are at variance with a recent report (Taveggia et al., 2008).
Supportive evidence for our findings (in addition to the data
below) is that heterozygous mice of either mutant allele (Nrg1
null or type III specific) express the same steady-state level of
NRG1 protein in brain (Figure S1E) and spinal cord (data not
shown) when compared to wild-type controls.
Myelination in the Absence of NRG1
Conventional Nrg1 null (/) mice die at embryonic day (E) 10.5,
prior to the generation of oligodendrocytes. We therefore gener-
ated conditional nullmutants to analyze possible defects of post-
natal CNS myelination. Mice carrying two ‘‘floxed’’ Nrg1 alleles
readily recombine exons 7–9 (essential for the EGF-like signaling
function) upon Cre expression in vivo (Li et al., 2002).
By crossbreeding floxedNrg1 to CamKII-Cre mice (Minichiello
et al., 1999), we obtained mutants lacking NRG1 in virtually all
projection neurons of the forebrain (Figures S2A and S2B) due
to Cre recombination at around postnatal day (P) 5, i.e., after582 Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc.oligodendrocyte specification but prior to subcortical myelina-
tion. Surprisingly, these mutants revealed no obvious develop-
mental abnormalities of the cortex, hippocampus, or the subcor-
tical white matter and showed no demyelination at older age
(Figures S2C and S2D). Although some myelination may have
occurred prior to the complete loss of NRG1 protein, we con-
clude that axonal NRG1 is not required to maintain CNS myelin
throughout adult life.
In order to address the developmental role of NRG1, we gener-
ated mutants using Cre recombination during the embryonic pe-
riod. By crossbreeding floxedNrg1withNEX-Cremice (Goebbels
et al., 2006), we disrupted NRG1 expression in newborn projec-
tion neurons of the cortex beginning at E12, including virtually all
neurons that extend axons into the corpus callosum (Figure S2E).
Surprisingly, NEX-Cre*Nrg1flox/flox mutants (‘‘NC*F/F’’) were
fully viable and indistinguishable in the cage from wild-type,
floxed (‘‘F/F’’), or NEX-Cre*Nrg1flox/+ controls. By morphological
and immunohistochemical criteria, the cortex and hippocampus
appeared normal (Figure 1A and data not shown). Efficient Cre-
mediated recombination was demonstrated by PCR analysis of
brain genomic DNA at 3 months of age (data not shown). Quan-
titative RT-PCR (data not shown) and western blotting
(Figure 1B) confirmed the reduction of NRG1, with residual ex-
pression most likely derived from glia (Esper et al., 2006). The
subcortical white matter with callosal axons from the overlying
cortical projection neurons was well developed (Figure 1A),
and myelin proteins were expressed at wild-type levels
(Figure 1C). We observed that myelinated fibers in the gray mat-
ter were normal in appearance when immunostained for 20 30-cy-
clic nucleotide phosphodiesterase (CNP) (Figures 1D and 1E) or
MBP (data not shown).
Using electron microscopy, myelin in the corpus callosum
(Figure 2A) and the spinal cord (data not shown) of 11-week-
old mice exhibited an intact ultrastructure. There were no
obvious differences in myelin sheath thickness or axonal size
distribution (Figure 2B). Also, at 2 years of age, there were no
signs of hypomyelination, demyelination, or axonal degeneration
in these mice, as demonstrated by electron microscopy of the
corpus callosum (Figures 2C and 2D).
To address a potential myelination delay in the absence of
NRG1, we immunostainedMBP at postnatal day (P) 10. Confocal
microscopy revealed unaltered numbers of MBP+ myelin pro-
files in the ventral corpus callosum of NC*FFmutants when com-
pared to controls (Figures 2E and 2F), demonstrating also that
timely myelination does not depend on NRG1.
Recently, hypomyelination in the CNS was reported in mice
lacking the expression of BACE1, a protease required for NRG1
processing (Hu et al., 2006; Willem et al., 2006). This suggests
that widespread BACE1 activity could provide a ‘‘paracrine’’
source of NRG1 originating from astrocytes (Esper et al., 2006)
that are genetically ‘‘wild-type’’ in NEX-Cre*NRG1flox/flox mice.
To inactivate possible astroglial and oligodendroglial sources of
NRG1 in the developing CNS, we generated conditional Emx-
Cre*Nrg1flox/flox null mutants that recombine efficiently in multipo-
tential progenitors of the embryonic forebrain (Gorski et al., 2002).
When analyzed at adult age (4 months), these mice were fully
myelinated (datanot shown)withoutmorphological orbiochemical
differences between wild-type and mutants (Figures S3A and
Neuron
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lysates (data not shown).
To completely abolish NRG1 expression in the developing
CNS, we generated conditional mutants using Nestin-Cre mice
(Tronche et al., 1999) (Figures S4A and S4B). Nestin-Cre*
Nrg1flox/flox mutants died about 16 hr after birth, i.e., later than
conventional Nrg1 type III null mutants (Wolpowitz et al., 2000)
but most likely with a lethal PNS defect (see below and Figures
S4C and S4D). When Nestin-Cremutants were analyzed at birth,
there was no detectable difference in brain morphology
compared to controls (Figure 3A). Western blotting showed
mutant brains to be almost completely NRG1 deficient
(Figure 3B, top). Also, in spinal cord, NRG1 was dramatically re-
duced (Figure 3B, bottom). Quantitative RT-PCR confirmed the
virtual absence of NRG1 in brain and a severe reduction in spinal
cord,with residual protein expressionmost likely derived from the
central branch of inefficiently recombined DRG neurons (Fig-
ure S4B). Spinal cord ventral roots, harboring the peripheral
aspects of motoneuron axons, as well as intercostal nerves,
almost completely lacked MBP and MPZ (P0) immunostaining,
demonstrating a block of Schwann cell differentiation in Nestin-
Cre*Nrg1flox/flox mutants (Figure 3C, middle and bottom panel).
Figure 1. Myelination inNEX-Cre*Nrg1flox/flox
Mice following Embryonic Recombination
(A) Neocortical development (Nissl staining) and
subcortical myelination (Gallyas silver impregna-
tion) appear normal in mutant mice (NC*F/F) com-
pared to controls (F/F). Depicted aremirror images
of coronal paraffin sections (7 mm) obtained at age
3 months. Scale bars, 1 mm.
(B) (Top) Western blot of protein lysates revealing
a loss of NRG1 in the neocortex ofNC*F/Fmutants
compared to controls (F/+) at 3 months of age.
(Bottom) Densitometric quantification reveals an
60% reduction of ‘‘full-length’’ NRG1 type III
(140 kDa) in NC*F/F mutants compared to con-
trols (F/+). Peak intensities (±SEM) were normal-
ized to GAPDH.
(C) Semiquantitative comparison of myelination
by western blotting myelin-specific proteins
from neocortical protein lysates of mutant mice
(NC*F/F; age 3 months) and littermate controls
(F/+). Steady-state levels of CNP, MAG, MBP,
and PLP/DM20 are normal.
(D and E) Myelinated tracts in neocortex and cor-
pus callosum of mutants (NC*F/F), as visualized
by immunostaining for CNP. Shown are coronal
paraffin sections (7 mm) of 3-month-old brains
frommutants (NC*F/F; right hemisphere) and con-
trol mice (F/F; left hemisphere). Scale bar, 1 mm.
Enlargements in (E) reveal individual fibers in corti-
cal layers II/III (boxed in upper panels). Scale bar,
50 mm.
Accordingly, immunostaining of sciatic
nerves derived from newborn Nestin-
Cre*Nrg1flox/flox mice revealed a strong
reduction in the number of MPZ-stained
myelinprofilesandKrox20-stainedmyelinat-
ing Schwann cells (Figures S4C and S4D).
Unexpectedly, the density of Olig2+ and MBP+ oligodendro-
cytes in the forebrain and spinal cord of these mice (Figure 3D
and data not shown) did not obviously differ in mutants and con-
trols (not quantified). Similarly, in the spinal cord, there was no
difference in the density of MBP+ myelin profiles in Nestin-
Cre*Nrg1flox/flox mice at birth (Figure 3C, upper panel). While
these data do not rule out a function for NRG1 as a growth or sur-
vival factor in the oligodendrocyte lineage, myelinating glial cells
clearly develop in the absence of NRG1 in vivo.
SinceNestin-Cre*Nrg1flox/floxmice diedmany days prior to my-
elin formation in the subcortical white matter, we also compared
long-term cocultures of wild-type oligodendrocytes and cortical
neurons, derived from embryonic wild-type or Nrg1 null mice.
As expected,myelination of theNRG1-deficientCNSaxonscould
be readily demonstrated by MBP immunostaining (Figure S5A)
and was independently observed in mixed brain cultures derived
solely from Nestin-Cre*Nrg1flox/flox mice (Figure S5B).
Myelination in the Absence of ErbB Signaling
The receptor tyrosine kinases ErbB2 and ErbB4 have been sug-
gested to control CNSmyelination in vivo (Vartanian et al., 1997),
while ErbB3 is not required for oligodendrocytic differentiationNeuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc. 583
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that lacked ErbB4 but were rescued from embryonic lethality
by means of an MHC-ErbB4 transgene expressed in the heart
(Tidcombe et al., 2003). Myelination appeared normal in the
CNS of these ErbB4 mutant mice, and there was no paucity of
Olig2+ oligodendrocytes (data not shown). Examination by elec-
tron microscopy revealed that homozygous ErbB4 null mutants
had no dysmyelination phenotype (Figure 4A). When quantified
in the corpus callosum, g ratios of myelinated axons in ErbB4
null mutant mice were the same as in controls (Figure 4B).
All neuregulins (NRG1, NRG2, NRG3) signal via ErbB2, ErbB3,
and ErbB4 receptor homo/heterodimers. Since ErbB2 lacks li-
gand-binding activity, the absence of both ErbB4 and ErbB3
from oligodendrocytes should suffice to completely eliminate
neuregulin signaling. We therefore generated a floxed allele of
the ErbB3 gene (T.M., H.W., and C.B., unpublished data) and
crossed these conditional mutants to a conditional null mutant
of the ErbB4 gene (Golub et al., 2004). Efficient recombination
of both genes in oligodendrocytes using CNP-Cre mice
(Lappe-Siefke et al., 2003) was confirmed by PCR on genomic
DNA derived from cortex and optic nerve (data not shown). As
expected, we detected by quantitative real-time PCR a severe
reduction in ErbB3 and ErbB4 expression in various CNS regions
(including optic nerve; Figures S3C and S3D) with residual mRNA
most likely derived from nonoligodendroglial cells.
CNP-Cre*ErbB3flox/– singlemutants (harboring one copy of the
conventional erbB3 null allele; Riethmacher et al., 1997) and
CNP-Cre*ErbB3flox/–*ErbB4flox/flox double mutants developed to
term. As expected, they displayed severe defects in PNS myeli-
nation (Figure 4C, bottom panel) and died in the second postna-
tal week. In striking contrast, electron microscopy of the optic
nerve and corpus callosum (Figure 4C, upper and middle panel),
g ratio measurements (Figure 4D, optic nerve only), and immu-
nostaining for MBP (data not shown) clearly demonstrated that
oligodendrocytes in ErbB3*ErbB4 double mutants (CNP-
Cre*ErbB3flox/–*ErbB4flox/flox) were capable of myelinating CNS
axons without delay and at the same level as control mice
(ErbB3flox/+*ErbB4flox/+), at least up to postnatal day P11.
Although we cannot rule out phenotypic differences at later
stages, we conclude that neuregulin/ErbB signaling is dispens-
able for CNS myelination in vivo.
Myelination in Response to NRG1 Type I
and Type III Overexpression
While myelination is independent of NRG1 in vivo, cells of the oli-
godendrocyte lineageclearly respond to the soluble growth factor
in culture (Calaora et al., 2001; Fernandez et al., 2000; Flores et al.,2000; Kim et al., 2003; Vartanian et al., 1997, 1999). To determine
what type of responsiveness oligodendrocytes show to axonal
NRG1 in vivo, we analyzed mice that overexpress cDNAs encod-
ing NRG1 type III (or NRG1 type I) under control of the neuronal
Thy1.2 promoter (Michailov et al., 2004). All NRG1overexpressing
mice were viable, but those with higher transgene dosage ex-
hibited ataxia that was most pronounced in homozygous mice
and that precluded detailed behavioral testing (data not shown).
The cause of these neurological abnormalities is unknown, but
given the broad expression of NRG1 and ErbB receptors, it could
be due to abnormal neuronal differentiation, synaptic function,
myelination, muscle development, or any combination of these.
By immunocytochemical analyses, the overexpression of NRG1
type I or NRG1 type III was widespread throughout the cortex
in all lines tested (Figure S6A and data not shown). Expression
analysisbyquantitativeRT-PCR (FigureS6B)andwesternblotting
(Figure S6C) demonstrated that NRG1 steady-state levels were
about 5-fold increased in adult heterozygous Thy1-Nrg1 type I
and type III transgenic mice.
Although morphological effects were not dramatic, we found
many ‘‘hypermyelinated’’ axons in the white matter regions ana-
lyzed. By electron microscopy, these axon-myelin units were
regularly spaced, and hypermyelination was clearly the result
of additional spiral wraps (Figure 5A). Unexpectedly, decreased
g ratios were also observed in Nrg1 type I transgenic mice
(Figure 5B), not only in type III transgenics (Figure 5C). This re-
vealed an important difference between the CNS and PNS,
where only the overexpression of axon-bound NRG1 type III
induces hypermyelination (Michailov et al., 2004). It is conceiv-
able that (shed) NRG1 type I acts by stimulating oligodendrocyte
production prior tomyelination and that an altered axon-glia ratio
is the basis of hypermyelination. We therefore compared the
density of CC1+ and CNP+ oligodendrocytes within the corpus
callosum of type I transgenic and wild-type mice but found no
significant differences (Figure S6D and data not shown).
Also axons within the cortex (layers II and III), which are gener-
ally of small caliber, showed a significant decrease of g ratios
(Figures 6A and6B). InNrg1 type I transgenics, such a hypermye-
lination was only a feature of axons thinner than 0.4 mm (leading
to a crossing of regression lines). Interestingly, in both transgenic
lines, we noticed a 2-fold increase ofmyelinated fibers per cross-
sectional area (upper cortical layers; white arrowheads in
Figure 6C) when compared to controls (Figure 6D). However,
there was no corresponding increase in the density of (CC1+)
oligodendrocytes (Figure 6E).
Possible explanations for the 2-fold higher ‘‘myelin-to-oligo-
dendrocyte’’ ratio in the cortex could be an increase of internodalFigure 2. Myelination and Myelin Ultrastructure in the Absence of NRG1
(A) Electron microscopy reveals normally myelinated axons in the corpus callosum of mutant (NC*F/F) and control mice (wild-type and F/+) at 11 weeks of age.
(B) G ratio analysis and scatter blots derived from electron micrographs of the corpus callosum in mutant (NC*F/F) and control mice, aged 11 weeks (n = 7 per
genotype). Quantitation of axon size distribution reveals no obvious difference between mutants (white bars) and controls (black bars).
(C) Also in aged mice (>18 months), electron microscopy of the corpus callosum demonstrates intact myelin profiles and the absence of neurodegeneration in
mutant (NC*F/F) and control (F/+) mice. Scale bars, 1 mm.
(D) Quantitation (g ratios) of the data in (C) reveals no dys- or demyelination (n = 3 per genotype).
(E) Callosal myelination in the absence of NRG1 is not delayed (age P10). Confocal microscopy of coronal vibratome sections (100 mm) immunostained for axons
derived from projection neurons (FNP7, red) andmyelin (MBP, green) demonstrates widespreadmyelination in the ventral corpus callosum ofmutant (NC*FF) and
control (F/F) mice. Scale bar, 10 mm (inset, 250 nm).
(F) Quantitation of MBP data in (E) (n = 3 per genotype; ±SEM).Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc. 585
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Neuregulin-1 and CNS MyelinationFigure 3. Oligodendrocytes Develop on Schedule in the Absence of NRG1
(A) Cortical and hippocampal development in Nestin (Nes)-Cre*Nrg1F/F mice that recombine in all neural precursor cells beginning at E8.5 is without obvious
delay or morphological defect (see Figure S2A). Shown are H&E-stained frontal brain sections (7 mm, paraffin) of newborn controls (Nrg1F/+, top) and mutants
(bottom). Scale bar, 500 mm.
(B) NRG1 is virtually absent in the CNS of newborn Nes-Cre*Nrg1F/F mutant mice. Western blot analysis of protein lysates prepared from brain (top panel) and
spinal cord (lower panel), comparing three control mice (Nrg1F/+, left) and three conditional null mutants (Nes-Cre*Nrg1F/F, right). Densitometry of brain and
spinal cord immunoblots revealed an 95% reduction of NRG1 in mutants compared to controls. Mean intensities (±SEM) were normalized to a-tubulin. One
brain (upper lane 3) was isolated 2 hr after natural death, showing some postmortem proteolysis. Molecular weights of marker proteins are indicated (asterisks
denote unspecific bands; loading control, tubulin).
(C) Impaired peripheral but not central myelination. (Top) Immunostaining of the ventro-medial spinal cord from newbornmice reveals the normal density of MBP+
myelin profiles (in red) in NRG1-deficient (Nes-Cre*Nrg1F/F, right) and control mice (Nrg1F/+, left). Neurons are stained for Neu-N (in green). (Middle) Immunos-
taining of cross-sections at the thoracic level for MBP (in red) and myelin protein zero (P0; in green). Note the almost complete absence of MBP and P0 in the
ventral roots (VR; also marked ‘‘PNS’’) of newborn Nes-Cre*Nrg1F/F mutants (right). In contrast, littermate Nrg1F/+ controls (left) exhibit numerous myelinated586 Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc.
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Neuregulin-1 and CNS Myelinationlength and/or a higher number of internodes (i.e., oligodendro-
cyte processes) in NRG1 overexpressing mice. Since an unbi-
ased quantitation of internodal length is difficult within cortical
sections, we performed confocal microscopy and three-dimen-
sional cell tracing of selected, singly located (CNP-stained)
oligodendrocytes in layers II and III of the cingulate and primary
motor cortex (Figure 7A). In the absence of pathological signs,
the average number of processes (Figure 7B), process branch
points (Figure 7C), and process length including internodal mye-
lin (Figure 7D) was not significantly altered in Nrg1 mutants and
NRG1 type III overexpressing mice. Only the average ‘‘territory’’
of these oligodendrocytes (Figure 7E) was significantly higher
in transgenics (+50%), similar to the increased volume of the
oligodendroglial somata (Figure 7F). Thus, cortical hyper-
myelination cannot be fully explained by a numerical increase
Figure 4. Myelination in the Absence of
ErbB3 and ErbB4 Receptors
(A) Electron micrographs showing myelinated
axons of the anterior corpus callosum in adult
wild-type mice (labeled ‘‘control’’) and transgeni-
cally rescued ErbB4 single mutants (genotype
MHC-ErbB4*ErbB4–/–), labeled ‘‘ErbB4/.’’
Scale bar, 2 mm.
(B) Quantitation of myelin sheath thickness in the
corpus callosum by g ratio analysis of electron mi-
crographs, comparing control mice (black circles,
n = 3) and rescued ErbB4/ mutants (n = 3, open
circles). Scatter plot displays g ratios of individual
fibers as a function of the respective axon diame-
ter. Myelin sheath thickness is not significantly
different.
(C)Electronmicrographsof theopticnerve (top), cor-
pus callosum (middle), and sciatic nerve (bottom)
at age P11 from ErbB3*ErbB4 double mutants
(right; genotype Cnp-Cre*ErbB3F/-*ErbB4F/F) and
controls (genotype ErbB3F/+*ErbB4F/+). Axons
in the optic nerve and corpus callosum of
ErbB3*ErbB4 double mutants are normally mye-
linated, whereas myelination of the sciatic nerve
is severely impaired. Scale bars, 1 mm (optic
nerve, corpus callosum); 2 mm (sciatic nerve).
(D) Quantitation of myelin sheath thickness (g
ratios) and axon size distribution for the optic
nerve of ErbB3*ErbB4 double mutants and con-
trols (age P11; n = 3 per genotype) reveals no sig-
nificant difference between mutants (white circles
and bars) and controls (black circles and bars).
of oligodendrocyte processes in the cor-
tex of NRG1 type III overexpressing
mice. Outside the cortex, we never found
‘‘ectopic’’ ensheathment of axons that
normally remain unmyelinated (such as
mossy fibers in the hippocampus), although in transgenic mice
dentate gyrus granule cells expressed visibly more NRG1 (data
not shown).
While myelination was not delayed even in the absence of
NRG1 (Figures 2E and 2F), there was clear evidence for prema-
ture myelination in NRG1 type III overexpressing mice
(Figure 8A). For example, Nrg1 mRNA in retinal ganglion cells
was further enhanced in early postnatal mice by expression of
the Thy1-Nrg1 type III transgene (Figures 8B and 8C). In these
developing optic nerves, we determined a 3-fold higher number
of myelinated axons than in controls (day P6; Figure 8D), without
a corresponding shift of oligodendrocyte numbers (Figure 8E).
This demonstrates that NRG1 can initiate the myelination pro-
gram inCNSdevelopment, a function normally provided by a dis-
tinct (yet unknown) axonal signaling system. We also conclude(MBP+/P0+, merged) axons. Note the presence of MBP+ oligodendrocytes in the ventro-lateral spinal cord (marked ‘‘CNS’’) in both mutants and controls. (Bot-
tom) Immunostaining of longitudinal sections of the intercostal nerve (ICN) reveals absence of P0-stained fibers (in green) in newborn Nes-Cre*Nrg1F/Fmutants
(right) when compared to littermate controls (left). Scale bars, 50 mm.
(D) Olig2+ oligodendrocytes (in red) are present at a normal density andwith a similar distribution in the forebrain of newbornmutantmice (Nes-Cre*Nrg1F/F, right)
compared to controls (Nrg1F/+, left). Boxed areas in upper panel are enlarged in lower panel. Neurons are stained for NeuN (in green). Scale bars, 200 mm (upper
panel), 100 mm (lower panel).Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc. 587
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Neuregulin-1 and CNS MyelinationFigure 5. Transgenic Overexpression of NRG1 Type I or Type III
Causes Hypermyelination
(A) Electron microscopy of hypermyelinated callosal axons in transgenic mice
(age 4.5 months) overexpressing (Ai) NRG1 type I and (Aii) NRG1 type III under
control of the neuronal Thy1.2 promoter. (Aiii) Ultrastructure of CNSmyelin and
membrane spacing is indistinguishable between transgene expressing (type I
tg) and wild-type (WT) axons, suggesting that hypermyelination is caused by
additional membrane wraps. Scale bars, 1 mm (Ai and Aii); 50 nm (Aiii).
(B) CNS hypermyelination in NRG1 type I overexpressing mice. Morphometric
data were obtained from 4.5-month-old mice (n = 3 per genotype) following
electron microscopy of spinal cord (ventro-medial region, cervical segment
7) and corpus callosum (caudal region). (Upper panels) When g ratios were588 Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc.from this unexpected result that in normal development the
onset of CNS myelination is likely determined by the degree of
neuronal differentiation, not by the timing of an intrinsic oligoden-
drocyte differentiation program.
CNS Remyelination in NRG1 Type I and III
Overexpressing Mice
To test whether NRG1 would have a similar stimulating effect on
CNS remyelination, we induced focal demyelination by injecting
lysolecthin into the ventrolateral region of the spinal cord. Sur-
prisingly, while axons in Nrg1 overexpressing mice were clearly
hypermyelinated on the contralateral side (Figure S7A), the
extent of axonal remyelination in the lesion, when quantified by
electronmicroscopy, was no different betweenNrg1 type I trans-
genic, Nrg1 type III transgenic, andwild-typemice (Figures S7B–
S7D). This is reminiscent of experiments in which both direct
infusion and systemic delivery of rhGGF-2 (NRG1 type II) do
not alter remyelination (Penderis et al., 2003) in a nonimmune,
gliotoxin model of demyelination. Interestingly, in lesions of
Nrg1 type III tg mice, Schwann cell remyelination showed
hypermyelination, in line with earlier observations in the PNS
(Michailov et al., 2004).
DISCUSSION
In the PNS, the entire program of glial differentiation and myeli-
nation is controlled byNRG1 type III (Garratt et al., 2000a; Jessen
and Mirsky, 2005; Nave and Salzer, 2006), and many studies
have reported that oligodendrocytes respond to NRG1 in vitro
and ex vivo (Calaora et al., 2001; Canoll et al., 1996; Fernandez
et al., 2000; Flores et al., 2000; Sussman et al., 2005; Vartanian
et al., 1997, 1999). This suggested that NRG1 may also be the
growth factor responsible for regulating CNSmyelination, a find-
ing that would have important clinical implications. In multiple
sclerosis, the endogenous repair of demyelinated lesions could
be NRG1 dependent (ffrench-Constant et al., 2004). Moreover,
schizophrenia is a complex disease that has been associated
with specific Nrg1 haplotypes (Hall et al., 2006; Stefansson
et al., 2002) and independently with myelin abnormalities (Davis
et al., 2003; Hakak et al., 2001). Thus, the control of subcortical
myelination by NRG1 could be amissing link (Corfas et al., 2004).
The Role of Neuregulins and ErbB Receptors
in Myelination
Using a set of mutant and transgenic mice, we have analyzed the
function of NRG1/ErbB signaling in oligodendrocytic differentia-
tion and myelination in vivo. We quantified the impact of altered
Nrg1 gene dosage and studied mutants with Cre-mediatedNrg1
plotted as a function of axon size, randomly chosen fibers in spinal cord
(left) and corpus callosum (right) were on avarage hypermyelinated (open rect-
angles, transgenic; closed rectangles, wild-type; p < 0.01). (Lower panels) The
size distribution of axons in the same areas was not obviously increased
by neuronal NRG1 type I overexpression (white bar, transgenic; black bar,
wild-type).
(C) CNS hypermyelination in NRG1 type III overexpressing mice. Same analy-
sis as in (B), with reduced g ratios demonstrating a significant increase of
myelin volume (p < 0.01) in brains (left) and spinal cord (right) of Nrg1 type III
transgenic mice.
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Neuregulin-1 and CNS MyelinationFigure 6. Transgenic Overexpression of
NRG1 Type I or NRG1 Type III Stimulates
Myelination in Neocortex
(A) Quantitation of cortical hypermyelination in
NRG1 type I overexpressing mice. Morphometric
data were obtained from 4.5-month-old animals
(n = 3 per genotype) following electronmicroscopy
of neocortical layers II/III. When g ratios were plot-
ted as a function of axon size for randomly chosen
fibers in the neocortex, hypermyelination was
a feature of only the smallest (<0.4 mm) caliber
axons (p < 0.01), leading to crossed regression
lines.
(B) Cortical hypermyelination in Nrg1 type III trans-
genic mice. Same analysis as in (A), with reduced
g ratios, demonstrating a significant increase of
myelin volume (p < 0.01) in brains and spinal
cord of Nrg1 type III transgenic mice.
(C) Electron microscopy of cortical layers II/III in
4.5-month-old mice (sagittal sections). Myelinated
small-caliber axons can be recognized (some
marked by white arrowheads) in wild-type mice
(Ci), andmore numerous inNrg1 type I transgenics
(Cii) and Nrg1 type III transgenics (Ciii). Higher
magnification of boxed area (in [Ciii]) is shown on
the right, depicting a normal and hypermyelinated
axon (Civ). Scale bars, 10 mm (Ci–Ciii) and 500 nm
(Civ).
(D) Quantification of myelin profiles (from [C]) with
ten micrographs per animal analyzed (n = 3 per
genotype; image size 440 mm2). Compared to
wild-type, both NRG1 type I and NRG1 type III
transgenic mice have a higher number of intracort-
ical myelinated axons in layers II/III (p < 0.01).
(E) Intracortical density of CC1-stained oligoden-
drocytes (neocortex, layer II/III) of 4.5-month-old
Nrg1 type I transgenic mice (n = 3) is unchanged
compared to wild-type controls (n = 2). Quantifica-
tion (error bars, ±SD) of three images (700 mm2)
per mouse.nullmutations in cortical projection neurons, occurring either be-
fore or after oligodendrocytic specification, i.e., at E10 (Emx-
Cre), E12 (NEX-Cre), or at P5 (CamKII-Cre). Contrary to our
expectations, the complete absence of neuronal NRG1 did not
perturb oligodendrocyte development and myelination in vivo.
Even Nestin-Cre*NRG1flox/flox mice exhibited normal specifica-
tion of oligodendrocytes that developed on schedule (Figure 3)
until early demise of these animals (the cause of death is presum-
ably unrelated to CNS myelination).
At the receptor level, only ErbB3 and ErbB4 can bind to neure-
gulins (NRG1-3). ErbB1/EGFR can regulate oligodendrocyte
precursor development (Aguirre et al., 2007) but fails to bind neu-
regulins. ErbB2 has no functional ligand-binding domain. Thus,
oligodendrocytes lacking both ErbB3 and ErbB4 are incapable
of transmitting signals fromNRG1, NRG2, or NRG3. Most impor-
tantly, these double mutant oligodendrocytes survive and myeli-
nate CNS axons in vivo, in marked contrast to double-mutant
Schwann cells (Figure 4). This finding demonstrates that, indeed,
neuregulin signaling is dispensable for CNS myelination, at least
during postnatal stages.
Our results are at odds with previous reports that suggested
that NRG1 is required for oligodendrocyte survival and differen-tiation in culture (Calaora et al., 2001; Canoll et al., 1996; Flores
et al., 2000; Kim et al., 2003; Sussman et al., 2005; Vartanian
et al., 1997). Specifically, the discrepancy between the present
in vivo study and previous ex vivo analyses of null mutant mice
is intriguing. Oligodendrocytes from Nrg1 null or ErbB2 null
mutant mice failed to differentiate within spinal cord explants
(Vartanian et al., 1999; Park et al., 2001). We have currently no
explanation for these findings other than a speculative model
that the electrical activity of axons may have evolved as a ‘‘mye-
lination signal’’ in the CNS. Perhaps in explant cultures NRG1/
ErbB signaling (i.e., the ancestral axonal myelination signal)
can compensate for the absence of electrical activity in
axons—but obviously not in cultures obtained from Nrg1 or
ErbB mutant mice.
Recently, Taveggia et al. (2008) reported cortical hypomyeli-
nation in Nrg1 type III heterozygous mice (Wolpowitz et al.,
2000). This presents a discrepancy with our findings in the
same strain of mutants (see Figures S1C and S1D) as well as
in Nrg1 null heterozygotes (Figures S1A and S1B; all on C57BL
background) and remains unexplained. Our data are supported
by unaltered NRG1 protein level in the brains of heterozygote
Nrg1 (type III and null mutant) mice (Figure S1E) and theNeuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc. 589
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of modifier genes in different mouse colonies could potentially
explain such discrepancies.
Also, reports of CNS hypomyelination in mice overexpressing
‘‘dominant-negative’’ ErbB proteins under control of oligoden-
drocyte-specific promoters (Kim et al., 2003; Roy et al., 2007)
are at variance with our findings. Unspecific side effects are
the most likely explanation. For example, dominant-negative
ErbB4 interacts with ErbB1/EGFR (Jones et al., 1999), a receptor
regulating the development of oligodendrocyte precursor cells
(Aguirre et al., 2007). Truncated ErbB receptors may also
‘‘trap’’ wild-type ErbB4 at specific sites in the glial-axonal junc-
tion (since mutant heterodimers will not endocytose at the nor-
mal rate). Truncated receptor dimers may occupy PDZ-binding
sites or simply displace other (not yet identified) oligodendroglial
receptors, which then fail to transmit axonal signals, all of which
would constitute a ‘‘dominant-negative’’ effect. We finally note
the general susceptibility of oligodendrocytes to membrane
Figure 7. Oligodendrocyte Morphology
(A) Two-dimensional representations of three-di-
mensional tracings of CNP-stained oligodendro-
cytes from layers II and III of the cingulate and
primary motor cortex (age 6 months). Three
examples from NEX-Cre*Nrg1flox/flox mutant
(NC*F/F), control (Nrg1F/F), and Nrg1 type III over-
expressing mice (Nrg1 type III) are shown. Each
color represents a primary cell process.
(B–F) Quantitation of primary process number (in
[B]), number of nodal branch points (in [C]), avar-
age process length (including internodal myelin;
in [D]), average 3D oligodendrocyte territory (in
[E]), and average oligodendrocyte soma volume
(in [F]), comparing NEX-Cre*F/F (NC*F/F), Nrg1F/F,
and Nrg1 type III mice (12–15 cells from three
mice per genotype). Error bars, SEM. Significance
test: two-tailed t test with Welch’s correction or
Kruskal-Wallis test.
protein overexpression (Kagawa et al.,
1994; Readhead et al., 1994; Tuohy
et al., 2004; Turnley et al., 1991), because
the expression level of dominant-nega-
tive receptors in transgenic oligoden-
drocytes cannot be predicted from the
chosen promoter.
Can our in vivo results be explained by
functional compensation between NRG1
and the structurally related growth factor
Neuregulin-2 (NRG2) (Carraway et al.,
1997)? Nrg2 null mutant mice are myelin-
ated (Britto et al., 2004), but coexpres-
sion of NRG1 and NRG2 within the CNS
is limited (Busfield et al., 1997; Longart
et al., 2004) (C.L. et al., unpublished
data). Moreover, transgenic overexpres-
sion of NRG2 failed to increase myelin
thickness in the CNS (T.M.F., M.H.S.,
C.L., and K.-A.N., unpublished data).
Third, NRG2 is expressed in both motoneurons (Rimer et al.,
2004) and DRG neurons (Figure S6E) but obviously fails to com-
pensate for the lack of NRG1 expression in the PNS. Another
candidate for compensation is Neuregulin-3 (NRG3), a more dis-
tantly related growth factor that is widely expressed in the CNS
(Zhang et al., 1997). Again, Nrg3 null mutants are viable and nor-
mally myelinated (T.M., A.N.G., and C.B., unpublished data). All
this is in agreement with normal myelination of conditional
ErbB3*ErbB4 double mutant mice.
Interestingly, a mild CNS hypomyelination (in addition to
peripheral dysmyelination) was reported for Bace1 mutant
mice (Hu et al., 2006). While PNS effects in these mice are
likely NRG1 dependent (Willem et al., 2006), our data suggest
that in the CNS other proteins must be the relevant BACE1 tar-
gets. Since timely myelination requires the electrical activity of
axons, the b2 subunit of the voltage-gated sodium channel
(Kim et al., 2007) is an attractive candidate for BACE1
processing.590 Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc.
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neuronal overexpression of NRG1 in transgenic mice stimulated
myelination, with little difference between NRG1 type III and type
I isoforms. Perinatal overexpression of NRG1 type III also
increased the soma size of oligodendrocytes. In contrast, prolif-
eration of oligodendrocyte precursors was unaltered. Thus,
neuronal NRG1 type III (even at several-fold elevated expression
levels) appears ineffective in stimulating OPC proliferation. We
hypothesize that NRG1 promotes oligodendrocyte growth by
activating the PI3K/TOR/S6K pathway, because a similar ‘‘un-
coupling’’ of oligodendrocyte proliferation and differentiation
is observed in conditional mutants of the Pten gene (S.G. and
K.-A.N., unpublished data).
That overexpression of NRG1 in retinal ganglion cells causes
even premature myelination of the optic nerve is remarkable. It
addresses the question whether myelination is developmentally
controlled by neuronal/axonal or oligodendroglial differentiation.
Our experiments reveal that manipulating neuronal differentia-
tion is sufficient to trigger premature myelination, implying that
oligodendrocytes are already myelination competent and thus
‘‘waiting’’ for axonal signals. The remyelination experiments
further reveal that oligodendrocytes lose this responsiveness
to NRG1 at an older age. This is in marked difference to Schwann
cells that occasionally invade the same CNS lesion where they
clearly hypermyelinate the NRG1 type III overexpressing axons
(data not shown).
Figure 8. NRG1 Type III Stimulates Prema-
ture Myelination of the Optic Nerve
(A) Electron micrographs of developing optic
nerves from wild-type (left) and Nrg1 type III trans-
genic mice (middle) at age P6, revealing single
myelin profiles (arrowheads, quantified in [D]).
Myelinated axons in boxed area (middle panel)
are magnified on the right. Asterisks mark nuclei
of oligodendrocytes. Scale bars, 5 mm.
(B) ByRT-PCR, Nrg1 type III mRNA is detectable in
the eye of wild-type mice at age P1 and P30 (brain
mRNA serving as internal positive controls; b-actin
internal control).
(C) By transgene-specific RT-PCR, type III mRNA
is detectable in the eyes of postnatal (P1 and
P30) Nrg1 type III transgenic mice, but not in
wild-type (WT). Spinal cord mRNA (sc, age P1)
as positive internal control; b-actin internal control.
(D and E) Higher number of myelinated axonal pro-
files (in [D]; p < 0.05) but equal number of oligoden-
drocytes (in [E]) in the optic nerve of 6-day-old
Nrg1 type III transgenic mice (gray bars) when
compared to age-matched controls (black bars).
Quantification is from semithin cross-sections
(WT, n = 5; Nrg1 type III transgenics, n = 6). Error
bars, SEM (unpaired, two-sided t test).
Possible Roles of NRG1/ErbB
Signaling in Oligodendrocytes
If not required for myelination, are other
oligodendroglial functions regulated by
neuregulins in the CNS? Oligodendro-
cytes and NG2+ precursor cells are
known to express NMDA, AMPA, and kainate receptors, similar
to neurons and astrocytes, which coexpress ErbB4 with these
glutamate receptors (Wong, 2006; Verkhratsky and Kirchhoff,
2007). Since NRG1/ErbB signaling has been implicated in the
subcellular targeting and endocytosis of synaptic glutamate re-
ceptors (Gu et al., 2005; Kwon et al., 2005), it may serve a similar
function for glutamate receptors on oligodendrocytes.
NRG1 may also have more subtle functions in the plasticity of
cortical myelination. This relates to our observation of a 2-fold
higher density of myelinated axons within the neocortex of
Nrg1-transgenic mice (a number unmatched by an increase of
oligodendrocyte density). Does NRG1 stimulate the generation
of myelinating glial processes? Cultured neurons and oligoden-
drocytes reportedly increase the number of processes when
NRG1 is added to the medium (Canoll et al., 1996, 1999). How-
ever, by three-dimensional cell tracing, cortical oligoden-
drocytes revealed about the same number of primary and
secondary branches (per cell), independent of the axonal
NRG1 expression level. Thus, the increased ‘‘myelin-to-oligo-
dendrocyte’’ ratio is more likely caused by slightly longer inter-
nodes (which are virtually impossible to quantify in the cortex).
In conclusion, our data suggest that CNS evolution has made
vertebrate oligodendrocytes independent from NRG1, presum-
ably the ancestral signal on axons that is necessary and suffi-
cient for myelination by Schwann cells. Perhaps, a simple sys-
tem (represented by NRG1 type III/ErbB signaling to SchwannNeuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc. 591
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includes neuronal activity as a myelination signal. Recently iden-
tified signaling components that serve different roles in CNS and
PNS myelination include purinergic receptors and activity-
dependent release of ATP (Fields and Burnstock, 2006; Stevens
et al., 2002). That CNS and PNS employ distinct mechanisms of
glial specification and myelination control is consistent with
distinct responses of oligodendrocytes and Schwann cells to
neurotrophins (Chan et al., 2004).
Relevance to Neuropsychiatric Disease
With respect to human disease,Nrg1 is an attractive susceptibil-
ity gene for schizophrenia (Stefansson et al., 2002), because this
factor has been implicated in neuronal migration, synaptic plas-
ticity, and myelination, all processes independently associated
with schizophrenia (Bartzokis, 2002; Corfas et al., 2004). In par-
ticular, cortical white matter abnormalities have been repeatedly
reported in SZ patients, which includes the reduced expression
of myelin-related genes (Hakak et al., 2001; Tkachev et al., 2003)
and decreased fractional anisotropy of callosal fibers by diffu-
sion tensor imaging (reviewed in Dwork et al., 2007). While al-
tered NRG1 expression levels could be a plausible cause and
‘‘missing link’’ to epidemiological data, our observation inmutant
mice suggests otherwise. Even conditional Nrg1 null mutants
revealed quantitatively normal expression levels of structural
myelin proteins (by western blotting or qRT-PCR) and also the
CNS myelin ultrastructure was unaltered. Although it is difficult
to make predictions across species, these data suggest that
small alterations of NRG1 expression, as predicted for the
Nrg1 at risk haplotype in humans, is highly unlikely to explain
the white matter abnormalities independently documented in
schizophrenia patients (Davis et al., 2003). However, several of
the mouse mutants described here will be useful to study other
schizophrenia-relevant functions in vivo, such as the role of the
Nrg1 gene in synaptic plasticity and cognitive functions.
EXPERIMENTAL PROCEDURES
Transgenic and Mutant Mice
The generation and genotyping of mice with null alleles of Nrg1 (Meyer et al.,
1997), ErbB3 (Riethmacher et al., 1997), and ErbB4 (Tidcombe et al., 2003),
conditional null alleles of Nrg1 (Li et al., 2002), ErbB3 (T.M. and C.B. unpub-
lished), and ErbB4 (Golub et al., 2004), and Nrg1 type I and type III transgenes
(Michailov et al., 2004) have been described. Floxed alleles of Nrg1 are genet-
ically null for alpha-NRG1 isoforms, but based on normal g ratios in compari-
son to wild-type and Nrg1 null heterozygotes (data not shown), they can be
considered controls.
Cre driver lines Nestin-Cre (Tronche et al., 1999), Emx1-Cre (Gorski et al.,
2002), NEX-Cre (Goebbels et al., 2006), CamKII alpha-Cre (Minichiello et al.,
1999), and CNP-Cre (Lappe-Siefke et al., 2003), and Cre reporter lines
R26R-lacZ (Soriano, 1999) and floxtauGFP-lacZ (Hippenmeyer et al., 2005)
were also genotyped as described. For PCR, we isolated genomic DNA
from tail biopsies, using Invisorb Spin tissue Mini Kit (Invitek), according to
the manufacturer’s directions. For routine genotyping, we used PCR primers
in a coamplification reaction. Primer sequences are available upon request.
All animal experiments were carried out in compliance with approved animal
policies of the Max Planck Institute of Experimental Medicine.
RNA Analysis
Total RNA was extracted using Qiazol Reagent according to the manufac-
turer’s instructions (QIAGEN). The integrity of purified RNA was confirmed592 Neuron 59, 581–595, August 28, 2008 ª2008 Elsevier Inc.using the Agilent 2100Bioanalyser (Agilent Technologies). ForRT-PCRanalysis,
cDNA was synthesized from total RNA using random nonamer primers and
Superscript III RNase H reverse transcriptase (Invitrogen). Quantitative real-
time PCR was carried out using the ABI Prism 7700 Sequence Detection Sys-
tem and SYBRGreen Master Mix according to the manufacturer’s instructions
(Applied Biosystems). Reactions were carried out at least in triplicate. The
relative quantity (RQ) of RNA was calculated using 7500 Fast System SDS
software Ver 1.3 (Applied Biosystems). Results were depicted as histograms
(generated by Microsoft Excel 2003) of normalized RQ values, with maximum
RQ value in a given group normalized to 100%. PCR primer sequences are
available upon request.
Protein Analysis
Protein lysates were prepared using an Ultraturrax (T8). Tissues were homog-
enized in 1 ml of modified RIPA buffer and protease inhibitors (Complete
tablets, Roche). For western blotting, 50 mg (for NRG1) or 1–5 mg (for myelin
proteins) of cortical or total brain lysate was size-separated on 8%–10%
(NRG1) or 12% (myelin proteins) SDS-polyacrylamide gels and blotted onto
PVDF membranes (Hybond-P) following instructions from Invitrogen. Mem-
branes were incubated with primary antibodies as described in Supplemental
Data. The densitometeric analysis of scanned ECL films was carried out using
QuantityOne and ImageJ software from BioRad.
Histology and Immunostaining
Mice (P7 and older) were anesthetizedwith avertin and perfusedwith 4%para-
formaldehyde in 0.1MPBS. Brains, spinal cords, and sciatic nerveswere post-
fixed in 4% paraformaldehyde for 1 hr to overnight at 4C and embedded in
paraplast. Microtome sections (5–7 mm) were haematoxylin-eosin (H&E) or
Nissl stained for studying brain cytoarchitecture. Myelinated fibers were visu-
alized by Gallyas silver staining. Axonal architecture of the neocortex was
studied by Bielschowsky silver impregnation. For immunofluorescent staining,
paraffin sections were incubated overnight with primary antibodies against
CNP (mM; 1:150, Sigma), GFAP (pRb; 1:200, DAKO), MBP (pRb; 1:500;
DAKO), CC-1 (mM; 1:50; Calbiochem), NeuN (mM; 1:100, Chemicon), Olig2
(pRb; 1:20,000, a gift of C. Stiles), FNP7 (mM; 1:150, Zytomed Systems),
Krox20 (pRb; 1:400, a gift of D. Meijer), NRG1 (pRb; 1:100, Santa Cruz
Biotech), and MPZ (mM; 1:1000, a gift from J.J. Archelos). Sections were
further incubated with their corresponding secondary Cy2 (1:100, Jackson
ImmunoResearch) or Cy3 (1:1000, Jackson ImmunoResearch) antibody for
1 hr at room temperature. For DAB-based immunostaining, the Dako-LSAB2
kit was used according to the manufacturer’s instructions. Digital images of
stained sections were obtained using Axiophot (Zeiss, Germany) and DMRXA
(Leica, Germany) microscopes and Openlab 3.1.1 software (Improvision). All
images were processed with Photoshop CS and Illustrator 10 software
(Adobe).
Imaging Oligodendrocyte Morphology
Sections were immunostained as described in Supplemental Data. A Zeiss la-
ser-scanning confocal microscope (Meta 510) was used to acquire z stacks of
OLs at optical slices of 0.53 mm with a 633 objective (1.4 numerical aperture).
Confocal z stacks were used to trace 12 to 15 individual OLs per genotype
(from n = 3mice each) with the AutoNeuron software package from the Neuro-
lucida three-dimensional cell tracing system (MBF Biosciences, Williston, VT).
Cell tracings were analyzed with the Neuroexplorer software (MBF Biosci-
ences, Williston, VT). Statistical Data analysis (two-tailed t test with Welch’s
correction and one-way ANOVA test or Kruskal-Wallis test) was performed
using the GraphPad Prism software package.
Electron Microscopy and Morphometry
Mice were perfused with 4% paraformaldehyde and 2.5% glutaraldehyde in
0.1 M PBS. Spinal cord, cortex, corpus callosum, optic nerves, and sciatic
nerves were removed, contrasted with osmium tetroxide, and Epon embed-
ded. Semithin sections (0.5 mm) were cut using a microtome (Leica, RM
2155) with a diamond knife (Histo HI 4317, Diatome). Sections were stained
with azur II-methylenblue for 1 min at 60C. Light microscopic observation
was with a 1003 lens (Leica DMRXA), and images were digitalized and ana-
lyzed with Openlab 3.1.1 and Scian Image software. For electron microscopy
Neuron
Neuregulin-1 and CNS Myelinationof cortex, corpus callosum, optic nerve, and sciatic nerve, ultrathin (50–70 nm)
sections were stained with 1% uranylacetate solution and analyzed using
a Zeiss EM10 or EM109 (Leo). The g ratio was determined by dividing the cir-
cumference of an axon (without myelin) by the circumference of the same axon
including myelin. At least 100 fibers per animal were analyzed, using three to
six animals per genotype. Statistical analyses were performed using Statistica
6.0 (StatSoft, Tulsa, USA).
SUPPLEMENTAL DATA
The Supplemental Data include figures and Supplemental Experimental Pro-
cedures and can be found with this article online at http://www.neuron.org/
cgi/content/full/59/4/581/DC1/.
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